NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, News, & Analysis

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) posted its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.50. The biotechnology company had revenue of $13 million for the quarter, compared to analyst estimates of $15.83 million. Momenta Pharmaceuticals had a negative return on equity of 40.55% and a negative net margin of 128.49%. The business's revenue was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.50) EPS. View Momenta Pharmaceuticals' Earnings History.

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Momenta Pharmaceuticals.

7 equities research analysts have issued 12-month price objectives for Momenta Pharmaceuticals' stock. Their predictions range from $14.00 to $24.00. On average, they anticipate Momenta Pharmaceuticals' stock price to reach $17.00 in the next twelve months. This suggests that the stock has a possible downside of 37.5%. View Analyst Price Targets for Momenta Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Momenta Pharmaceuticals.

Some companies that are related to Momenta Pharmaceuticals include AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA) and Sangamo Therapeutics (SGMO).

Press coverage about MNTA stock has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a coverage optimism score of 0.05 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.86 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Momenta Pharmaceuticals.

Momenta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.05%), FMR LLC (14.99%), RA Capital Management LLC (4.73%), Janus Henderson Group PLC (2.85%), Renaissance Technologies LLC (1.78%) and Fiera Capital Corp (1.41%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, Richard P Shea, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.

MNTA stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Renaissance Technologies LLC, Bank of New York Mellon Corp, Strs Ohio, Fisher Asset Management LLC, California Public Employees Retirement System, Municipal Employees Retirement System of Michigan and Arizona State Retirement System. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Santiago Arroyo, Scott M Storer and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.

MNTA stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, BlackRock Inc., Janus Henderson Group PLC, First Trust Advisors LP, FMR LLC, PNC Financial Services Group Inc., Bank of America Corp DE and Bank of Montreal Can. View Insider Buying and Selling for Momenta Pharmaceuticals.

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MNTA stock can currently be purchased for approximately $27.20.

Momenta Pharmaceuticals has a market capitalization of $2.03 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]